ReviewMetabolites2026
Nutritional Strategies for Selected MASLD Outcomes: Metabolic Remodeling, Liver-Aging Biomarkers, and Public Health Priorities.
Review in Metabolites, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) connects nutritional exposures with cardiometabolic risk and vulnerability during aging. Nutrition provides an actionable foundation for care, while metabolomics may clarify variation in dietary responses. This critical narrative review integrates nutritional trials, metabolic and aging studies, and clinical guidance from PubMed, Web of Science, Scopus, and Google Scholar through September 2026 using a documented narrative-search and selection process. Evidence is differentiated by population, original disease definition, design, tissue source, biomarker role, and outcome. Sustained weight reduction and selected dietary interventions, including Mediterranean-style and other high-quality dietary patterns, can improve selected hepatic or cardiometabolic outcomes, although comparative superiority is inconsistent. Lipid handling, nutrient sensing, mitochondrial function, and microbial metabolites provide mechanistic context. Metabolomic signatures characterize dietary exposure and metabolic adaptation, whereas direct evidence that nutritional treatment slows liver-specific biological aging remains absent: such evidence would require a defined MASLD population, a nutritional intervention, and a liver-tissue or independently validated liver-specific aging endpoint. Nutritional effects on aging measures are heterogeneous and largely derived from populations not selected for MASLD. The synthesis identifies public health priorities: reducing cumulative dietary risk, integrating nutritional care with fibrosis and cardiometabolic assessment, preserving muscle function, and expanding access to sustained support. A qualification framework distinguishes exposure, association, prognosis, response, and candidate surrogate roles while incorporating cost and equity. Accessible nutritional care can improve selected MASLD outcomes now; aging-informed precision nutrition remains investigational until molecular testing improves decisions and durable health benefits beyond established assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.